secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2023-10-24T23:59:59+00:00
Accession:  0001493152-23-038045
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TenX Keane Acquisition signs definitive merger with Citius Oncology; $675M equity value
--------------------------------------------------------------------------------

- Deal values Citius Oncology at $675M; Citius Pharma receives 67.5M shares at $10/share.
- Citius Pharma to retain ~90% majority ownership in publicly listed New Citius Oncology post-close.
- Transaction expected to close first half 2024, subject to shareholder and regulatory approvals.
- TenX to domesticate from Cayman Islands to Delaware and rename to Citius Oncology, Inc.
- Sponsor 10XYZ Holdings agrees to support deal and waive redemption rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/0001493152-23-038045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000149315223038045/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer